PE20040907A1 - Derivados de anilinopirazol - Google Patents
Derivados de anilinopirazolInfo
- Publication number
- PE20040907A1 PE20040907A1 PE2003001198A PE2003001198A PE20040907A1 PE 20040907 A1 PE20040907 A1 PE 20040907A1 PE 2003001198 A PE2003001198 A PE 2003001198A PE 2003001198 A PE2003001198 A PE 2003001198A PE 20040907 A1 PE20040907 A1 PE 20040907A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- diabetes
- amino
- methyl
- acid
- Prior art date
Links
- CMAOIURPBUCSJE-UHFFFAOYSA-N n-phenyl-1h-pyrazol-5-amine Chemical class C=1C=CC=CC=1NC=1C=CNN=1 CMAOIURPBUCSJE-UHFFFAOYSA-N 0.000 title 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 2
- -1 ANILINOPYRAZOLE DERIVATIVE COMPOUNDS Chemical class 0.000 abstract 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract 1
- 239000005711 Benzoic acid Substances 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 1
- 235000010233 benzoic acid Nutrition 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000004104 gestational diabetes Diseases 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE ANILINOPIRAZOL DE FORMULA I, INCLUYENDO SUS SALES FARMACEUTICAMENTE ACEPTABLES, EN DONDE R ES H O ALQUILO C1-C6; R1 ES H, ALQUILO C1-C6, ALQUENILO C3-C6, ALQUINILO C3-C6, ENTRE OTROS; R2 ES H, HALO, ALQUILO C1-C6, CICLOALQUILO C3-C6, ENTRE OTROS; O CUANDO R1 Y R2 SON ALQUILO C1-C6, PUEDEN FORMAR, CONJUNTAMENTE CON LOS ATOMOS DE C A LOS CUALES ESTAN UNIDOS, UN ANILLO CARBOCICLICO DE 5-6 MIEMBROS; R3 ES ALQUILO C1-C6, CICLOALQUILO C3-C6, BENCILO, ENTRE OTROS; R4 ES ALQUILO C1-C6, ALCOXI C1-C6, ALQUILTIO C1-C6, ENTRE OTROS; n ES 0, 1, 2 o 3; X ES CO2R8, CONR5R6, SO2NHR7, ENTRE OTROS; R5 ES H, ALQUILO C1-C6, ALQUILO C2-C6 SUSTITUIDO CON OR6, ENTRE OTROS; R6 ES H O ALQUILO C1-C6; O R5 Y R6 CONJUNTAMENTE CON EL ATOMO DE N, AL CUAL ESTAN UNIDOS, PUEDEN FORMAR UN ANILLO PIPERIDINA, MORFOLINA, TIOMORFOLINA, ENTRE OTRAS; R7 ES H o METILO; R8 ES H, ALQUILO C1-C6, BENCILO, ENTRE OTROS; SON COMPUESTOS PREFERIDOS: ACIDO 2-[(3-TER-BUTIL-1-METIL-1H-PIRAZOL-5-IL) AMINO]-5-METOXIBENZOICO; ACIDO 2-{[3-METIL-1-(2-METILFENIL)-1H-PIRAZOL-5-IL]AMINO}BENZAMIDA; ACIDO 2-{[3-(4-FLUORFENIL)-1-(2-METILFENIL)-1H-PIRAZOL-5-IL]AMINO}BENZOICO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON UTILES PARA TRATAR LA DIABETES DE TIPO 1, DIABETES DE TIPO 2, DIABETES QUE APARECE EN LA PUBERTAD, DIABETES AUTO-INMUNE LATENTE EN ADULTOS, DIABETES GESTACIONAL
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42991702P | 2002-11-27 | 2002-11-27 | |
| US49821403P | 2003-08-27 | 2003-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040907A1 true PE20040907A1 (es) | 2005-01-27 |
Family
ID=32474531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003001198A PE20040907A1 (es) | 2002-11-27 | 2003-11-26 | Derivados de anilinopirazol |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7265144B2 (es) |
| EP (1) | EP1567517A1 (es) |
| JP (1) | JP2006510728A (es) |
| KR (1) | KR20050085170A (es) |
| AR (1) | AR042067A1 (es) |
| AU (2) | AU2003295890A1 (es) |
| BR (1) | BR0316723A (es) |
| CA (1) | CA2507186A1 (es) |
| HN (1) | HN2003000379A (es) |
| MX (1) | MXPA05004621A (es) |
| MY (1) | MY141528A (es) |
| PE (1) | PE20040907A1 (es) |
| PL (1) | PL377164A1 (es) |
| TW (1) | TW200418803A (es) |
| UY (1) | UY28098A1 (es) |
| WO (2) | WO2004050650A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007538102A (ja) * | 2004-05-20 | 2007-12-27 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 糖尿病の処置に有用な５−アニリノ−４−ヘテロアリールピラゾール誘導体 |
| SI1860098T1 (sl) | 2005-03-16 | 2013-03-29 | Toyama Chemical Co., Ltd. | Nov derivat antranilne kisline ali sol le-tega |
| JP5193861B2 (ja) * | 2005-07-07 | 2013-05-08 | アボット・ラボラトリーズ | アポトーシス促進剤 |
| CA2620425A1 (en) * | 2005-08-31 | 2007-03-08 | Bayer Healthcare Llc | Anilinopyrazole derivatives useful for the treatment of diabetes |
| WO2007129195A2 (en) * | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| EP2049493B1 (en) * | 2006-07-31 | 2012-03-21 | Cadila Healthcare Limited | Compounds suitable as modulators of hdl |
| KR101101675B1 (ko) | 2006-10-02 | 2011-12-30 | 노파르티스 아게 | 단백질 키나제 억제제로서의 화합물 및 조성물 |
| JPWO2008093639A1 (ja) * | 2007-01-29 | 2010-05-20 | 武田薬品工業株式会社 | ピラゾール化合物 |
| WO2009045761A1 (en) * | 2007-09-28 | 2009-04-09 | Absolute Science, Inc. | Compounds and methods for treating zinc matrix metalloprotease dependent diseases |
| DE102008039083A1 (de) | 2008-08-21 | 2010-02-25 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Aminopyrazole und ihre Verwendung |
| DE102008039082A1 (de) | 2008-08-21 | 2010-02-25 | Bayer Schering Pharma Aktiengesellschaft | Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung |
| US20110190285A1 (en) * | 2008-09-19 | 2011-08-04 | Absolute Science, Inc. | Methods of treating a botulinum toxin related condition in a subject |
| ES2443947T3 (es) | 2008-09-25 | 2014-02-21 | F. Hoffmann-La Roche Ag | Derivados de 3-amino-indazol o de 3-amino-4,5,6,7-tetrahidro-indazol |
| AR075713A1 (es) | 2009-03-03 | 2011-04-20 | Du Pont | Pirazoles fungicidas |
| TWI504350B (zh) * | 2010-09-01 | 2015-10-21 | Du Pont | 殺真菌吡唑及其混合物 |
| TWI568721B (zh) | 2012-02-01 | 2017-02-01 | 杜邦股份有限公司 | 殺真菌之吡唑混合物 |
| JP6299591B2 (ja) | 2012-07-03 | 2018-03-28 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
| CN103074693A (zh) * | 2013-01-18 | 2013-05-01 | 桐昆集团股份有限公司 | 带双导丝辊的poy纺丝卷绕装置 |
| US9394269B2 (en) | 2013-12-23 | 2016-07-19 | Amazentis Sa | Process-scale synthesis of urolithins |
| WO2016204270A1 (ja) * | 2015-06-18 | 2016-12-22 | 日本曹達株式会社 | ジアリールアゾール化合物および有害生物防除剤 |
| DK3632904T3 (da) * | 2017-05-26 | 2022-07-25 | Jiangsu Atom Bioscience And Pharmaceutical Co Ltd | URAT1-inhibitorer til at fremme urinsyreudskillelse |
| US11312722B2 (en) * | 2019-05-08 | 2022-04-26 | Trustees Of Boston University | Hsp90 inhibitors and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL263568A (es) | 1960-04-14 | |||
| US3790576A (en) * | 1972-03-20 | 1974-02-05 | Parke Davis & Co | 9 substituted 4,9-dihydro-1,3,4,4-tetraalkyl-1h-pyrazolo(3,4-b)quinolines |
| HUT69739A (en) | 1992-03-26 | 1995-09-28 | Dowelanco | Process for producing n-heterocyclic nitroanilines and fungicides containing the compounds |
| DE69532817T2 (de) | 1994-11-10 | 2005-01-13 | Millenium Pharmaceuticals, Inc., Cambridge | Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose |
| DE19532066A1 (de) | 1995-08-31 | 1997-03-06 | Bayer Ag | Substituierte 5-Aminopyrazole |
| FR2763334A1 (fr) * | 1997-05-13 | 1998-11-20 | Lipha | Derives anthraniliques |
| US5998424A (en) | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
| US5942520A (en) | 1998-01-27 | 1999-08-24 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines |
| JP2006519234A (ja) * | 2003-02-27 | 2006-08-24 | スミスクライン ビーチャム コーポレーション | 新規化合物 |
-
2003
- 2003-11-18 AR ARP030104252A patent/AR042067A1/es unknown
- 2003-11-21 US US10/719,485 patent/US7265144B2/en not_active Expired - Fee Related
- 2003-11-21 WO PCT/US2003/037578 patent/WO2004050650A1/en not_active Ceased
- 2003-11-21 AU AU2003295890A patent/AU2003295890A1/en not_active Abandoned
- 2003-11-25 WO PCT/US2003/037829 patent/WO2004050651A1/en not_active Ceased
- 2003-11-25 KR KR1020057009560A patent/KR20050085170A/ko not_active Withdrawn
- 2003-11-25 EP EP03812454A patent/EP1567517A1/en not_active Withdrawn
- 2003-11-25 CA CA002507186A patent/CA2507186A1/en not_active Abandoned
- 2003-11-25 AU AU2003297565A patent/AU2003297565A1/en not_active Abandoned
- 2003-11-25 MX MXPA05004621A patent/MXPA05004621A/es not_active Application Discontinuation
- 2003-11-25 BR BR0316723-2A patent/BR0316723A/pt not_active IP Right Cessation
- 2003-11-25 PL PL377164A patent/PL377164A1/pl not_active Application Discontinuation
- 2003-11-25 JP JP2004570952A patent/JP2006510728A/ja active Pending
- 2003-11-26 PE PE2003001198A patent/PE20040907A1/es not_active Application Discontinuation
- 2003-11-26 HN HN2003000379A patent/HN2003000379A/es unknown
- 2003-11-26 TW TW092133242A patent/TW200418803A/zh unknown
- 2003-11-26 UY UY28098A patent/UY28098A1/es not_active Application Discontinuation
- 2003-11-27 MY MYPI20034545A patent/MY141528A/en unknown
-
2007
- 2007-08-31 US US11/897,620 patent/US20080064734A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1567517A1 (en) | 2005-08-31 |
| US20040157904A1 (en) | 2004-08-12 |
| BR0316723A (pt) | 2005-10-18 |
| US20080064734A1 (en) | 2008-03-13 |
| HN2003000379A (es) | 2005-12-20 |
| JP2006510728A (ja) | 2006-03-30 |
| HK1087103A1 (zh) | 2006-10-06 |
| AR042067A1 (es) | 2005-06-08 |
| CA2507186A1 (en) | 2004-06-17 |
| WO2004050651A1 (en) | 2004-06-17 |
| AU2003295890A1 (en) | 2004-06-23 |
| WO2004050650A1 (en) | 2004-06-17 |
| MXPA05004621A (es) | 2005-06-08 |
| PL377164A1 (pl) | 2006-01-23 |
| UY28098A1 (es) | 2004-06-30 |
| AU2003297565A1 (en) | 2004-06-23 |
| US7265144B2 (en) | 2007-09-04 |
| MY141528A (en) | 2010-05-14 |
| KR20050085170A (ko) | 2005-08-29 |
| TW200418803A (en) | 2004-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040907A1 (es) | Derivados de anilinopirazol | |
| BRPI0608732A2 (pt) | composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto | |
| CR7496A (es) | Piridinoilpiperidinas como agonistas de 5- ht1f | |
| PE20040909A1 (es) | Derivados fluoroglicosidos aromaticos con afinidad por el receptor sglt2 | |
| CO5560610A2 (es) | Derivados de yodobenzopiran-4-ona que tienen actividad fungicida | |
| UY26727A1 (es) | Derivados de tropano útiles en terapia | |
| PE20050012A1 (es) | Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2 | |
| AR030959A1 (es) | Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen | |
| PE20040844A1 (es) | Acidos fenilaceticos y derivados como inhibidores de la cox-2 | |
| DOP2001000170A (es) | Derivados de tiofeno utiles como agentes anticancesoros | |
| AR050261A2 (es) | Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento | |
| CO5550421A2 (es) | Derivados de indol utiles para el tratamiento de enfermeda- des | |
| PE20050948A1 (es) | Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv | |
| ATE286872T1 (de) | Stabile salze neuartiger derivate von 3,3- diphenylpropylaminen | |
| PE2799A1 (es) | Lactamas e imidas heterociclicas de aralquilo y aralquilideno | |
| NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| NO308248B1 (no) | Forbindelser som er anvendbare som antiproliferative midler og GARFT-inhibitorer, samt farmasøytisk preparat | |
| NO20025640D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| NO983493L (no) | Nye benzimidazol-, benzoksazol- og benzotiazolforbindelser, fremgangsmÕte ved fremstilling derav og farmas°ytiske sammensetninger inneholdende slike | |
| CO5720995A2 (es) | Compuesto novedoso | |
| EE200000059A (et) | Tetrahüdro-gamma-karboliinid | |
| AR044453A1 (es) | Derivados de metoxi-pirazin-tienil sulfonamida | |
| AR003137A1 (es) | Una composicion farmaceutica para tratar la leucemia | |
| AR056574A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
| AR043273A1 (es) | Derivados de bifenilo, su uso, un proceso para prepararlos y medicamentos que los contienen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |